Percutaneous treatment of spinal metastatic disease 2021-The changing Paradigm. Mark Coates

Print Friendly, PDF & Email


Due to chemotherapy  advances people are living  much longer with cancer  and Spinal metastatic disease is a more significant issue.Stereotactic Radiation and Percutaneous ablative techniques are changing the management of this condition.This presentation will discuss the available options in 2021.

Mark is head of MSK and Spinal radiology at CDHB (Christchurch) and Pacific Radiology Group and responsible for the delivery of all aspects of Spinal Diagnosis and Intervention.
He has an active interest in diagnosis and treatment of Bone tumours and is the lead radiologist for the regional Bone and Soft tissue Sarcoma service and the Myeloma MDT and has been on the MOH National working groups in both of these areas.
Together with Kris Dalzell, Rowan Schouten, Jeremy Evison he has set up the first MDT in New Zealand for the multidisciplinary management of Spinal Tumours/Spinal Metastatic disease. He is a Part II FRANZCR examiner,executive member of RANZCR-NZ) and AMSIG (Australian and New Zealand Musculoskeletal Imaging Group) and a member of the RANZCR MSK/Spinal special interest group which liaises regularly with ACC.